TG Therapeutics Inc to Post FY2018 Earnings of ($2.30) Per Share, Jefferies Financial Group Forecasts (NASDAQ:TGTX)

TG Therapeutics Inc (NASDAQ:TGTX) – Equities research analysts at Jefferies Financial Group dropped their FY2018 earnings estimates for TG Therapeutics in a report issued on Tuesday, March 26th, Zacks Investment Research reports. Jefferies Financial Group analyst C. Howerton now anticipates that the biopharmaceutical company will post earnings of ($2.30) per share for the year, down from their previous estimate of ($1.98). Jefferies Financial Group has a “Buy” rating and a $8.00 price objective on the stock. Jefferies Financial Group also issued estimates for TG Therapeutics’ FY2019 earnings at ($1.84) EPS and FY2020 earnings at ($1.26) EPS.

A number of other equities research analysts have also recently issued reports on TGTX. BidaskClub raised shares of TG Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 5th. Zacks Investment Research cut shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of TG Therapeutics in a research note on Friday, April 12th. Finally, ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. TG Therapeutics has a consensus rating of “Buy” and a consensus target price of $14.07.

Shares of TG Therapeutics stock traded down $0.31 during trading on Thursday, reaching $7.83. The company’s stock had a trading volume of 2,003,113 shares, compared to its average volume of 2,356,732. TG Therapeutics has a 52-week low of $3.32 and a 52-week high of $16.00. The stock has a market capitalization of $688.81 million, a price-to-earnings ratio of -4.10 and a beta of 2.31.

Institutional investors and hedge funds have recently made changes to their positions in the business. Forbes J M & Co. LLP purchased a new stake in TG Therapeutics during the 4th quarter valued at $44,000. LPL Financial LLC purchased a new stake in TG Therapeutics during the 4th quarter valued at $49,000. NumerixS Investment Technologies Inc purchased a new stake in TG Therapeutics during the 4th quarter valued at $50,000. National Asset Management Inc. purchased a new stake in TG Therapeutics during the 4th quarter valued at $58,000. Finally, Stifel Financial Corp purchased a new stake in TG Therapeutics during the 4th quarter valued at $59,000. 55.59% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

Recommended Story: What is the Producer Price Index (PPI)?

Get a free copy of the Zacks research report on TG Therapeutics (TGTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.